ScinoPharm Completes China Plant - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ScinoPharm Completes China Plant



ScinoPharm has completed construction of  a R&D process-development center and a multipurpose API cGMP manufacturing plant in Changshu, China.
 
A total of $113 million was invested in this facility.  The new plant will work together with ScinoPharm Taiwan in the production of new and generic drugs for the international market as well as supply the local Chinese market.  The plant has already received drug production licenses from the Chinese FDA for four APIs products. The plant will also serve as the base for the company to develop its API business in China.  ScinoPharm has already developed nine of the top 20 oncological products used in China, according to the company.
 
The Changshu plant is equipped to manufacture high-potency, antitumor, hormonal-active pharmaceutical ingredients and intermediates in highly contained facilities. In addition, the plant is also able to manufacture new products in smaller quantities for sales evaluations and for GMP samples.
 
The company also has purchased an additional 108 acres of adjoining property to be used for the development of future API production lines and for the construction of future formulation production plants.

Source: ScinoPharm

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here